Sign in
CompletedPhase 1/2

Effects of Pioglitazone on Stress Reactivity and Alcohol Craving

Key facts

Who runs it
The University of Texas Health Science Center, Houston
Where
Houston, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
67 people enrolled
Started
12 May 2022
Ended
16 Aug 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Pioglitazone
  • Placebo
Record updated
27 August 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • treatment-seeking individuals diagnosed with Alcohol Use Disorder Diagnostic (AUD) and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
  • fluent in English
  • past month excessive alcohol use (>7 drinks/week for woman, >14 drinks/week for men, >3 drinks/occasion for women>4 drinks/occasion for men)
  • exhibit baseline measures of either 1) 8-23 on HAM-A indicative of mild to moderate anxiety, 2) 14-26 on PSS Score indicative of moderate stress, or 3) ≥2 on Drinking Motives Questionnaire (DMQ-R) questions related to drinking indicating that individuals drink at least "some of the time" to cope
  • exhibit increased stress reactivity (increased physiological response and/or self-report) at the baseline stress reactivity assessment
  • females will need to agree to use of barrier methods of contraception due to pioglitazone's effects on plasma concentrations of oral contraceptives

Who cannot take part

  • contraindicating pioglitazone pharmacotherapy or taking contraindicated medications (e.g., CYP2C8 inhibitors or inducers, antihyperglycemic medications)
  • greater than mild substance use disorder on drugs other than alcohol, nicotine, and marijuana
  • medical conditions (e.g., congestive heart failure, clinically significant edema, clinically significant liver disease, hypoglycemia, diabetes, history of bladder cancer)
  • have any other illness, condition, or use of medications, which in the opinion of the PI and/or admitting physician would preclude safe and/or successful completion of the study
  • Exhibit severe scores on the HAM-A, PSS, or PTSD checklist (PCL-5) - may be enrolled at the discretion of the admitting physician (Dr. Weaver)
  • physical dependence on alcohol (CIWAA > 10)
  • contraindications for taking pioglitazone
  • be pregnant, nursing, or planning on becoming pregnant during the course of the study

Where in United States

  • The University of Texas Health Science Center of HoustonHouston, United States

About the trial

What the trial wants to find out

The purpose of this study is to examine the effects of pioglitazone on stress-induced relapse risk in a laboratory model and to examine the effects of pioglitazone on drinking, stress/anxiety, and alcohol craving in the natural environment

The 2 groups in the trial

  • PioglitazoneTreatment being tested
  • PlaceboPlacebo, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
27 August 2025